Facebook
Twitter
LinkedIn
Forward
December 17, 2024, Nashville - Circling in on Evaporation: Dry Eye Disease Case Discussions
Tuesday, December 17, 2024
6:00 PM – 6:30 PM CT Attendee Check-In
6:30 PM – 8:30 PM CT CE Dinner Meeting
Fleming's Prime Steakhouse
2525 West End Avenue
Nashville, Tennessee
Target Audience
This educational activity is intended for optometrists.
Learning Objectives
After completing this activity, participants will be better able to:
- Review the function of the tear film in maintaining a healthy ocular surface
- Use diagnostic strategies to identify dry eye disease
- Identify treatments for a variety of patients with dry eye disease according to clinical evidence
Dry Eye Disease: Prevalence, Etiology, and Pathophysiology
Diagnosing DED
Case From the Files of Melissa Barnett, OD, FAAO, FSLS, FBCLA
Treating DED
Case From the Files of Melissa Barnett, OD, FAAO, FSLS, FBCLA
Concomitant Ocular Disease and DED
Case From the Files of Walter O. Whitley, OD, MBA, FAAO
Optimizing the Ocular Surface Prior to Ocular Surgery
Case from the files of Walter O. Whitley, OD, MBA, FAAO
Presenter
 | Marc R. Bloomenstein, OD, FAAO Director of Optometric Services Schwartz Laser Eye Center Scottsdale, Arizona |
Series Co-Chairs
 | Melissa Barnett, OD, FAAO, FSLS, FBCLA Director of Optometry University of California, Davis Davis, California |
 | Walter O. Whitley, OD, MBA, FAAO Director, Optometric Services Virginia Eye Consultants Virginia Beach, Virginia |
Disclosure Policy
MedEdicus requires that anyone who is in a position to control the content of this educational activity disclose all relevant financial relationships with any ineligible company. Financial relationship information is collected and resolved prior to the educational activity. All relevant relationships have been mitigated.
Faculty
Melissa Barnett, OD, is a consultant for CooperVision and Visus Therapeutics; is an advisory board member of ABB, AbbVie Inc, AccuLens, Azura Ophthalmics Ltd, Bausch & Lomb Incorporated, Bruder Healthcare, CooperVision, Dompé US, Inc, EveryDay Contacts, Johnson & Johnson Vision Care, Inc, Lenstechs, Mojo Vision Inc*, Novartis Pharmaceuticals Corporation, OCuSOFT Inc, Orasis Pharmaceuticals, Oyster Point Pharma, Inc, Percept Technologies Inc, RVL Pharmaceuticals, Scleral Lens Education Society, ScienceBased Health, Sight Sciences, Sjögren’s Syndrome Foundation, Sun Pharmaceutical Industries, Inc, Tarsus Pharmaceuticals, Inc, Vistakon, Visus Therapeutics, and Vyluma; and is on the speakers bureau for British Contact Lens Association, CooperVision, Gas Permeable Lens Institute, Oyster Point Pharma, Inc, RVL Pharmaceuticals, ScienceBased Health, Scleral Lens Education Society, Sjögren’s Syndrome Foundation, STAPLE Program, and Tarsus Pharmaceuticals, Inc.
Marc R. Bloomenstein, OD, is an advisory board member of AbbVie Inc, Alcon, Astellas Pharma Inc, Bausch & Lomb Incorporated, Johnson & Johnson Vision Care, Inc, Novartis Pharmaceuticals Corporation, OCuSOFT Inc, Oyster Point Pharma, Inc, Sight Sciences, STAAR Surgical, Sun Pharmaceutical Industries, Inc, and Thea Pharmaceuticals Limited; and is on the speakers bureau for AbbVie Inc, Bausch & Lomb Incorporated, Oyster Point Pharma, Inc, Sight Sciences, and Sun Pharmaceutical Industries, Inc.
Walter O. Whitley, OD, MBA, is a consultant for AbbVie Inc, Alcon, Aldeyra Therapeutics, Apellis Pharmaceuticals, Astellas Pharma Inc, Bruder Healthcare, Dompé US, Inc, Eyenovia, Inc, Heru, Inc, Mediprint, Novartis Pharmaceuticals Corporation, Oyster Point Pharma, Inc, Regener-Eyes, Tarsus Pharmaceuticals, Inc, and Thea Pharmaceuticals Limited; is an advisory board member of AbbVie Inc, Alcon, Bausch & Lomb Incorporated, Bruder Healthcare, Oyster Point Pharma, Inc, ScienceBased Health, Tarsus Pharmaceuticals, Inc, and Visus Therapeutics; is on the speakers bureau for AbbVie Inc, Alcon, Bausch & Lomb Incorporated, Oyster Point Pharma, Inc, and Sun Pharmaceutical Industries, Inc; and is a contracted researcher for Heru, Inc.
Planners, Managers, and Writers
MedEdicus planners and managers have no relevant relationships with ineligible companies to disclose.
* The financial relationship existed during the past 24 months but has now ended
Accreditation Statement
COPE approved for 2.0 CE credits for optometrists.
COPE Course ID: 89528-TD (Synchronous In Person)
COPE Course Category: Treatment/Management of Ocular Disease
Administrator: 
This activity, COPE Activity Number 129723, is accredited by COPE for continuing education for optometrists.
COPE advises optometrists to contact the State or Provincial Board where they are licensed for verification of what is acceptable for license renewal.
Disclosure of Commercial Support
MedEdicus LLC has received commercial support from Bausch & Lomb Incorporated for this activity in the form of an unrestricted educational grant.
The content of this COPE-accredited CE activity was planned and prepared independently by MedEdicus LLC without input from members of an ineligible company.
Off-Label Discussion
This educational activity may include discussion of unlabeled and/or investigational uses of drugs and devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.
Provider Contact Information
For questions about this educational activity, please contact MedEdicus LLC at info@mededicus.com.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of MedEdicus LLC or Bausch & Lomb Incorporated.
This CE activity is copyrighted to MedEdicus LLC ©2024. All rights reserved. MedEdicus does not claim copyright to material included herein owned by third parties for which attribution or citation has been made. 312
Available Credit
- 2.00 COPE
To register for this dinner meeting, please select the purple Take course button. You will receive an email confirmation. If you do not receive a confirmation, please check your spam folder or email info@mededicus.com.
We look forward to seeing you in Nashville on December 17!